Advertisement

Calciject

Main information

  • Trade name:
  • Calciject 20 CMD Solution for Injection
  • Available from:
  • Norbrook Laboratories Limited
  • Pharmaceutical form:
  • Solution for injection
  • Prescription type:
  • POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug
Advertisement

Documents

Localization

  • Available in:
  • Calciject 20 CMD Solution for Injection
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Sheep
  • Therapeutic area:
  • Mineral

Other information

Advertisement

Status

  • Source:
  • VMD - Veterinary Medicines Directorate
  • Authorization status:
  • Authorized
  • Authorization number:
  • 02000/4189
  • Authorization date:
  • 23-05-2000
  • Last update:
  • 21-12-2016

Summary of Product characteristics

Advertisement

13 March 2008

AN: 01250/2007

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Calciject 20 CMD Solution for Injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Active Substance:

Contains Calcium Borogluconate 20% w/v, Magnesium Hypophosphite

Hexahydrate 5% w/v and Glucose Monohydrate 22% w/v.

Each 400ml contains:

5.92g calcium (provided by calcium gluconate and calcium

borogluconate), 1.84g magnesium (provided by magnesium

hypophosphate hexahydrate) and 80g glucose as glucose

monohydrate. Also contains 3.40% w/v boric acid.

Excipients:

Chlorocresol 0.10

For a full list of excipients, see section 6.1

3. PHARMACEUTICAL FORM

Solution for injection

A clear pale yellow solution.

4. CLINICAL PARTICULARS

4.1 Target species

Sheep

4.2 Indications for use, specifying the target species

For the treatment of hypocalcaemia complicated by deficiency of

magnesium with accompanying hypoglycaemia. In the treatment of

pregnancy toxaemia and other metabolic imbalances in periparturient

sheep.

13 March 2008

AN: 01250/2007

4.3 Contraindications

Not to be administered by intravenous or intramuscular routes.

4.4 Special Warnings for each target species

No special warning.

4.5 Special precautions for use

(i) Special precautions for use in animals

The solution should be warmed to body temperature before

administration.

(ii) Special precautions to be taken by the person administering

the veterinary medicinal product to animals

Care should be taken to avoid accidental self-injection.

4.6 Adverse reactions (frequency and seriousness)

None.

4.7 Use during pregnancy, lactation or lay

Can be safely administered to pregnant and lactating animals.

4.8 Interaction with other medicinal products and other forms of

interaction

None.

4.9 Amounts to be administered and administration route

The solution should be warmed to body temperature before

administration by subcutaneous injection only. Observe aseptic

precautions.

Sheep: 50 - 80 ml

Message site gently after administration.

4.10 Overdose (symptoms, emergency procedures, antidotes), if

necessary

Not applicable.

4.11 Withdrawal period

13 March 2008

AN: 01250/2007

Sheep: Meat – Zero days

Milk – Zero hours

5. PHARMACOLOGICAL PROPERTIES

Pharmacotherapeutic group: Metabolic Preparation

ATC Vet Code: QA12AX

5.1 Pharmacodynamic properties

Milk fever, characterised by hypocalcaemia is caused by an acute drop

in the level of calcium in the blood. At parturition hypophosphataemia

and hypomagnesaemia can also occur. Administration by

subcutaneous injection replenishes plasma concentrations of calcium,

phosphate and magnesium ions. Dextrose is included as an energy

source to coincide with the high turnover of energy during lambing.

5.2 Pharmacokinetic properties

The absorption of magnesium takes place in the proximal small

intestine by active transport in a common pathway with calcium.

Magnesium ions are inefficiently absorbed from the gastro-intestinal

tract where absorption may be enhanced by the presence of vitamin D.

Magnesium salts are excreted mainly in the urine with small amounts in

milk, saliva and faeces. The normal range for magnesium in large

animals is 1.7-3.0mg/100ml and clinical signs appear when the level

drops below 1.0mg/100ml.

Blood glucose concentrations in healthy animals are closely controlled

and in hyperglycaemia the excess blood glucose is normally removed

from the circulation. The removal occurs by several routes including

renal clearance: The renal threshold of blood glucose is readily

exceeded.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Chlorocresol

Sodium Bicarbonate

Water for Injections

6.2 Incompatibilities

None Known.

6.3.1 Shelf life

13 March 2008

AN: 01250/2007

Shelf life of the veterinary medicinal product as packaged for sale:

Glass Bottles: 2 years, Polypropylene vials: 2 years.

Shelf life after first opening the immediate packaging: 28 days.

6.3.2 Special precautions for storage

(1) Once a vial has been broached the contents should be used

within 28 days

(2) Do not store above 25°C.

(3) Protect from light.

6.5 Nature and composition of immediate packaging

A clear, pale yellow aqueous solution packed in either 400 ml amber

type III glass bottles, with natural rubber wads and aluminium screw

caps or 400 ml polypropylene vials with bromobutyl bungs and

aluminium overseal.

6.6 Special precautions for the disposal of unused veterinary

medicinal product or waste materials derived from the use of such

products

Any unused veterinary medicinal product or waste materials derived

from such veterinary medicinal products should be disposed of in

accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited

Station Works

Newry

Co. Down, BT35 6JP

8. MARKETING AUTHORISATION NUMBER(S)

Vm 02000/4189

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

23 rd May 2000/23 rd May 2005

10. DATE OF REVISION OF THE TEXT

13 March 2008

There are no safety alerts related to this product.

Other products from the same company

Advertisement